Dupilumab for refractory sclerotic‐type cutaneous graft‐versus‐host disease
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19311 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Rohan Mital und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Skin Diseases, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Division of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, USA.
- Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Rohan Mital, Benjamin H Kaffenberger
Zitieren
APA
Mital, R., Penza, S. L., Choe, H. K., Chung, C. G., & Kaffenberger, B. H. (2023). Dupilumab for refractory sclerotic‐type cutaneous graft‐versus‐host disease. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19311
Vancouver
Mital R, Penza SL, Choe HK, Chung CG, Kaffenberger BH. Dupilumab for refractory sclerotic‐type cutaneous graft‐versus‐host disease. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19311
BibTeX
@article{Mital2023,
author = {Mital, Rohan and Penza, Sam L and Choe, Hannah K and Chung, Catherine G and Kaffenberger, Benjamin H},
title = {Dupilumab for refractory sclerotic‐type cutaneous graft‐versus‐host disease},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19311}
}
EUVIMED